HexaBody-DR5/DR5 (GEN1029)

HexaBody®-DR5/DR5 (GEN1029) is a mixture of two non-competing HexaBody molecules that target two distinct epitopes on death receptor 5 (DR5), a cell surface receptor that mediates a process called programmed cell death, which is very important for the natural elimination of cells. Increased expression of DR5 has been reported in several types of tumors. HexaBody-DR5/DR5 is the first HexaBody molecule to enter the clinic and it has potential in a variety of solid tumors including colorectal cancer, non-small cell lung cancer, triple negative breast cancer, renal cell cancer & urothelial cancer. A Phase I/II study in solid cancers is ongoing.

Back to top

HexaBody-DR5/DR5 has potential in a variety of solid tumors including colorectal cancer, non-small cell lung cancer, triple negative breast cancer, renal cell cancer, gastric cancer, pancreatic cancer & urothelial cancer. A Phase I/II study in solid cancers is ongoing. For more information, visit clinicaltrials.gov.

Back to top